Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
Dow Hits New All-Time High Close as Rescue Bill Passes
by Mark Vickery
Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.
BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.
VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study
by Zacks Equity Research
VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
5 Beaten-Down Stocks of Nasdaq ETF With Upside Potential
by Sweta Killa
We highlighted five stocks from the ETF that were hit badly in the tech rout but might reverse the trend, given their solid Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive earnings estimate revisions in a month.
Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains
by Zacks Equity Research
Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.
Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II
by Zacks Equity Research
Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.
IBM & Moderna Partner to Augment COVID-19 Vaccine Management
by Zacks Equity Research
IBM and Moderna (MRNA) team up to explore utility of hybrid cloud and blockchain technology to enhance COVID-19 vaccine management and stem the spread of the contagion.
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?
by Kevin Cook
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 High Earnings Yield Picks That Command Your Attention
by Rimmi Singhi
Level up your portfolio with high earnings yield stocks including ArcelorMittal (MT), Moderna, (MRNA), Shell (RDS.A), Magna (MGA), Winnebago (WGO).
Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
by Zacks Equity Research
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply
by Zacks Equity Research
Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
Top Stock Picks for Week of March 1, 2021
by Panel Of Zacks Experts
A Leader in Covid-19 Vaccine and a Company Showing Positivity.
Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit
by Zacks Equity Research
Perrigo (PRGO) reports dismal fourth-quarter 2020 results. The company signs deal to sell its generic drug business for $1.55 billion. Stock up.
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall
by Zacks Equity Research
Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.
Nasdaq ETF's Worst Day Since October: Stocks That Survived
by Sanghamitra Saha
The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.
Jobless Claims, Q4 GDP Dip; Durable Goods Soar +3.4%
by Mark Vickery
While jobless claims fell on weather-related issues, Durable Goods were up big for January.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Moderna (MRNA) Misses on Q4 Earnings, Eyes $18B in Vaccine Sales
by Zacks Equity Research
Moderna (MRNA) records product sales for the first time which comprises sales of its coronavirus vaccine, mRNA-1273. Stock up.